3071 - 3080 of 9148 Results
Title
Year
- Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease2018RESTRICTEDTitle: Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's diseaseJournal Name: Experimental NeurologyPublisher: Elsevier BVVol: 304Issue #:Start Page: 143End Page: 153Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.expneurol.2018.03.008Citation Count: 31
- Media hype: Patient and scientific perspectives on misleading medical news2017RESTRICTEDTitle: Media hype: Patient and scientific perspectives on misleading medical newsJournal Name: Movement DisordersPublisher: WileyVol: 32Issue #: 9Start Page: 1319End Page: 1323Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.26993Citation Count: 44
- Enabling breakthroughs in Parkinson’s disease with wearable technologies and big data analytics2016OPENTitle: Enabling breakthroughs in Parkinson’s disease with wearable technologies and big data analyticsJournal Name: mHealthPublisher: AME Publishing CompanyVol: 2Issue #:Start Page: 20End Page: 20Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.21037/mhealth.2016.04.02Best OA location URL: https://mhealth.amegroups.com/article/viewFile/10369/pdfCitation Count: 35
- Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primate model of Parkinson's disease2014RESTRICTEDTitle: Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primate model of Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 29Issue #: 6Start Page: 772End Page: 779Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.25859Citation Count: 40
-
OPENTitle: Nilotinib – Differentiating the Hope from the HypeJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 6Issue #: 3Start Page: 519End Page: 522Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-160904Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd160904?id=journal-of-parkinsons-disease%2Fjpd160904Citation Count: 32
-
OPENTitle: Impact of motor fluctuations on real-life gait in Parkinson’s patientsJournal Name: Gait & PosturePublisher: Elsevier BVVol: 62Issue #:Start Page: 388End Page: 394Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.gaitpost.2018.03.045Best OA location URL: https://publications.aston.ac.uk/id/eprint/33121/1/1_s2.0_S0966636218302832_main.pdfCitation Count: 34
-
OPENTitle: Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortiumJournal Name: Movement DisordersPublisher: WileyVol: 28Issue #: 12Start Page: 1740End Page: 1744Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.25600Best OA location URL: http://hdl.handle.net/11573/1383084Citation Count: 41
- Serum L-ornithine-derived polyamines as indicators of Parkinson disease progression2025RESTRICTEDTitle: Serum L-ornithine-derived polyamines as indicators of Parkinson disease progressionJournal Name: Journal of Neural TransmissionPublisher: Springer Science and Business Media LLCVol: 133Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00702-025-03007-wCitation Count: 1
-
OPENTitle: The commercial genetic testing landscape for Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 92Issue #:Start Page: 107End Page: 111Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.10.001Best OA location URL: http://www.prd-journal.com/article/S1353802021003564/pdfCitation Count: 29
-
OPENTitle: Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)Journal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 8Issue #: 2Start Page: 308End Page: 320Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.51236Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.51236Citation Count: 33